Biomobie Technology
[The Efficacy of BioBoosti 8 Minute Electromagnetic Cycles for the Treatment of Insomnia]

Medical Breakthrough with Biomobie Partner Harvard University


A study at Harvard University revealed that those 30-35% of the American population suffering insomnia now have a non-pharmaceutical option. Biomobie's non-pharmaceutical, non-invasive, precision technology device has been demonstrated to relieve insomnia using revolutionary bioelectricity according to clinical trials conducted by Harvard University.


Massive Insomnia Problem and Health Risk

In February, 2016, the Centers for Disease Control and Prevention (CDC) published a press release notifying the public that fully 1 out of every 3 adults in the United States reported obtaining less than the recommended seven hours of nightly sleep on a regular basis. During the course of a given year, up to 40% of the adult population in the United States reports experiencing insomnia, with 60% of the people reporting insomnia suffering from some type of chronic health disorder. Over half of Americans aged 65 or older reported sleeping less than seven hours a night.


The World Health Organization studied insomnia (2004) and reported that insomnia has been statistically associated with various medical conditions, including disorders of the cardiovascular, respiratory, gastrointestinal, renal and musculoskeletal systems. A large study of insomniacs showed that poor sleepers are more than twice as much at risk of ischemic heart disease as good sleepers. Most individuals develop cognitive deficits from chronic sleep debt after only a few nights of reduced sleep quality or quantity; new evidence suggests additional important health-related consequences of sleep debt related to common viral illnesses, diabetes, obesity, heart disease, depression and other age-related chronic disorders.

Harvard University
Brigham & Women's Hospital
John R. Graham Headache Center
Biomobie Corp., USA
Biomobie (Shanghai) Regenerative Medicine co., Ltd.

Scan qr code to share to WeChat